| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Memorial Sloan-Kettering Cancer Center, New York, New York 10021
To determine the potential role of p53 inactivation in prostate cancer, we studied a well characterized cohort of 86 patients treated with radical prostatectomy. We analyzed patterns of p53, mdm2, and p21/WAF1 expression by immunohistochemistry. Results were then correlated with clinicopathological parameters of poor outcome, including time to PSA relapse. In addition, data were also correlated with proliferative index, as assessed by Ki67 antigen detection. p53-positive phenotype, defined as identification of nuclear immunoreactivity in >20% of tumor cells, was observed in 6 of 86 cases (7%). An association was observed between p53-positive phenotype and decreased time to PSA relapse (P < 0.01). mdm2-positive phenotype, defined as 
20% of tumor cells displaying nuclear immunoreactivity, was observed in 28 of 86 cases (32.5%). mdm-2-positive phenotype was found to be associated with advanced stage (P = 0.009). p21-positive phenotype, defined as >5% of tumor cells with nuclear immunoreactivity, was observed in 28 of 86 cases (32.5%). An association was observed between p21-positive phenotype and high Ki67 proliferative index (P = 0.002). Patients with p21-positive phenotype had a significant association with decreased time to PSA relapse (P = 0.0165). In addition, a significant association was found between p21-positive phenotype and coexpression of mdm2 (P < 0.01). Forty-three of 86 cases (50%) were found to have one or more alterations, and patients with any alteration were found to have a higher rate of PSA relapse (P < 0.01). It is our hypothesis that a pathway of prostate cancer progression involves p53 inactivation caused by mdm2 overexpression and that p21 transactivation in this setting is due to an alternative signaling system, rather than through a p53-dependent mechanism.
This article has been cited by other articles:
|
|
 |
|
  M. Maguire, P. C. Nield, T. Devling, R. E. Jenkins, B. K. Park, R. Polanski, N. Vlatkovic, and M. T. Boyd MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination Cancer Res., May 1, 2008; 68(9): 3232 - 3242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Das, K. Wojno, and M. J. Imperiale BK Virus as a Cofactor in the Etiology of Prostate Cancer in Its Early Stages J. Virol., March 15, 2008; 82(6): 2705 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Yang, C. S. Zong, W. Xia, Y. Wei, M. Ali-Seyed, Z. Li, K. Broglio, D. A. Berry, and M.-C. Hung MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation. Mol. Cell. Biol., October 1, 2006; 26(19): 7269 - 7282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mikhail, E. Velazquez, R. Shapiro, R. Berman, A. Pavlick, L. Sorhaindo, J. Spira, C. Mir, K. S. Panageas, D. Polsky, et al. PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation Clin. Cancer Res., July 15, 2005; 11(14): 5153 - 5157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bianco, R. Caputo, R. Caputo, V. Damiano, S. De Placido, C. Ficorella, S. Agrawal, A. R. Bianco, F. Ciardiello, and G. Tortora Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4858 - 4864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Osman, H. Yee, S. S. Taneja, B. Levinson, A. Zeleniuch-Jacquotte, C. Chang, C. Nobert, and D. M. Nanus Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer Clin. Cancer Res., June 15, 2004; 10(12): 4096 - 4100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, H. Wang, G. Prasad, M. Li, D. Yu, J. A. Bonner, S. Agrawal, and R. Zhang Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models Clin. Cancer Res., February 15, 2004; 10(4): 1263 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Nantermet, J. Xu, Y. Yu, P. Hodor, D. Holder, S. Adamski, M. A. Gentile, D. B. Kimmel, S.-i. Harada, D. Gerhold, et al. Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland J. Biol. Chem., January 9, 2004; 279(2): 1310 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Caruso, B. Levinson, J. Melamed, R. Wieczorek, S. Taneja, D. Polsky, C. Chang, A. Zeleniuch-Jacquotte, K. Salnikow, H. Yee, et al. Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients Clin. Cancer Res., January 1, 2004; 10(1): 222 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. WANG, P. OLIVER, Z. ZHANG, S. AGRAWAL, and R. ZHANG Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides: In Vitro and in Vivo Activities and Mechanisms Ann. N.Y. Acad. Sci., December 1, 2003; 1002(1): 217 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hernandez, L. A. Maddison, Y. Wei, F. DeMayo, T. Petras, B. Li, J. R. Gingrich, J. M. Rosen, and N. M. Greenberg Prostate-Specific Expression of p53R172L Differentially Regulates p21, Bax, and mdm2 to Inhibit Prostate Cancer Progression and Prolong Survival Mol. Cancer Res., December 1, 2003; 1(14): 1036 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, M. Li, H. Wang, S. Agrawal, and R. Zhang Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy PNAS, September 30, 2003; 100(20): 11636 - 11641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Drobnjak, J. Melamed, S. Taneja, K. Melzer, R. Wieczorek, B. Levinson, A. Zeleniuch-Jacquotte, D. Polsky, J. Ferrara, R. Perez-Soler, et al. Altered Expression of p27 and Skp2 Proteins in Prostate Cancer of African-American Patients Clin. Cancer Res., July 1, 2003; 9(7): 2613 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. Roninson Tumor Cell Senescence in Cancer Treatment Cancer Res., June 1, 2003; 63(11): 2705 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Polsky, K. Melzer, C. Hazan, K. S. Panageas, K. Busam, M. Drobnjak, H. Kamino, J. G. Spira, A. W. Kopf, A. Houghton, et al. HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma J Natl Cancer Inst, December 4, 2002; 94(23): 1803 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Osman, E. Sherman, B. Singh, E. Venkatraman, M. Zelefsky, G. Bosl, H. Scher, J. Shah, A. Shaha, D. Kraus, et al. Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent J. Clin. Oncol., July 1, 2002; 20(13): 2980 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Claudio, A. Zamparelli, F. U. Garcia, L. Claudio, G. Ammirati, A. Farina, A. Bovicelli, G. Russo, G. G. Giordano, D. E. McGinnis, et al. Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27kip1, p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland Adenocarcinoma Clin. Cancer Res., June 1, 2002; 8(6): 1808 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fizazi, L. A. Martinez, C. R. Sikes, D. A. Johnston, L. C. Stephens, T. J. McDonnell, C. J. Logothetis, J. Trapman, L. L. Pisters, N. G. Ordonez, et al. The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2002; 8(3): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Long. G. Wang, L. Ossowski, and A. C. Ferrari Overexpressed Androgen Receptor Linked to p21WAF1 Silencing May Be Responsible for Androgen Independence and Resistance to Apoptosis of a Prostate Cancer Cell Line Cancer Res., October 1, 2001; 61(20): 7544 - 7551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Polsky, B. C. Bastian, C. Hazan, K. Melzer, J. Pack, A. Houghton, K. Busam, C. Cordon-Cardo, and I. Osman HDM2 Protein Overexpression, but not Gene Amplification, is Related to Tumorigenesis of Cutaneous Melanoma Cancer Res., October 1, 2001; 61(20): 7642 - 7646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Osman, H. I. Scher, M. Drobnjak, D. Verbel, M. Morris, D. Agus, J. S. Ross, and C. Cordon-Cardo HER-2/neu (p185neu) Protein Expression in the Natural or Treated History of Prostate Cancer Clin. Cancer Res., September 1, 2001; 7(9): 2643 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, H. Asch, and M. F. Kulesz-Martin Functional Quantification of DNA-binding Proteins p53 and Estrogen Receptor in Cells and Tumor Tissues by DNA Affinity Immunoblotting Cancer Res., July 1, 2001; 61(14): 5402 - 5406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Salnikow, M. Costa, W. D. Figg, and M. V. Blagosklonny Hyperinducibility of Hypoxia-responsive Genes without p53/p21-dependent Checkpoint in Aggressive Prostate Cancer Cancer Res., October 1, 2000; 60(20): 5630 - 5634. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
